Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803663 | 0.96 | JAK2 (0.54) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL883610 | 0.92 | USP30 (0.55) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL29782573 | 0.92 | USP30 (0.55) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL28030596 | 0.89 | USP30 (0.62) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL28030595 | 0.89 | USP30 (0.62) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL7761338 | 0.89 | USP30 (0.62) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL29418473 | 0.89 | SIGMAR1 (0.55) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL1781222 | 0.87 | SMN1; SMN2 (0.57) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL31187310 | 0.86 | JAK2 (0.47) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL29593677 | 0.85 | JAK2 (0.51) | SIGMAR1JAK2JAK1USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | SIGMAR1 369/4885JAK2 1298/4885JAK1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.